Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor.

MLA

Vora, Sona M., et al. “Expanded Eligibility for Emerging Therapies in Sickle Cell Disease in the UK - Crizanlizumab and Voxelotor.” British Journal of Haematology, vol. 197, no. 4, May 2022, pp. 502–04. EBSCOhost, https://doi.org/10.1111/bjh.18059.

APA

Vora, S. M., Boyd, S., Denny, N., Jackson, E., Roy, N. B. A., Howard, J., & Lugthart, S. (2022). Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor. British Journal of Haematology, 197(4), 502–504. https://doi.org/10.1111/bjh.18059

Chicago

Vora, Sona M, Stephen Boyd, Nicholas Denny, Elizabeth Jackson, Noemi B A Roy, Jo Howard, and Sanne Lugthart. 2022. “Expanded Eligibility for Emerging Therapies in Sickle Cell Disease in the UK - Crizanlizumab and Voxelotor.” British Journal of Haematology 197 (4): 502–4. doi:10.1111/bjh.18059.